Otsuki T, Hata H, Harada N, Matsuzaki H, Yata K, Wada H, Yawata Y, Ueki A, Yamada O
Department of Hygiene, Kawasaki Medical School, Kurashiki, Okayama, Japan.
Int J Hematol. 2000 Aug;72(2):216-22.
To clarify cellular biological varieties of myeloma cells, biological differences were analyzed between 2 human myeloma cell lines, KMS-12-PE and KMS-12-BM, derived from pleural effusion and bone marrow, respectively, of a single patient. Although both lines were considered to be derived from the same clone because both had the same chromosomal marker and immunoglobulin H rearrangement, several biological differences were noted. CD11a and CD20 were highly expressed in the KMS-12-BM line, whereas the KMS-12-PE line showed a higher expression of CD7 and CD95/Fas. Although growth was stimulated in KMS-12-BM by interleukin-6 and interferon-alpha, it was inhibited in KMS-12-PE. In addition, apoptosis inhibitors Bcl-2 and Bcl-X(L) were highly expressed in KMS-12-BM cells. Because KMS-12-PE was cultivated 2 months before KMS-12-BM, these differences might be related to their origin (pleural effusion and bone marrow) or the phases of disease progression. However, these biological differences may help clarify myeloma cell biology and lead to improvement in treatment for myeloma patients.
为了阐明骨髓瘤细胞的细胞生物学差异，我们分析了来自同一名患者胸腔积液和骨髓的两种人骨髓瘤细胞系KMS-12-PE和KMS-12-BM之间的生物学差异。尽管由于这两种细胞系具有相同的染色体标记和免疫球蛋白H重排，被认为源自同一克隆，但仍发现了一些生物学差异。CD11a和CD20在KMS-12-BM细胞系中高表达，而KMS-12-PE细胞系则显示出较高的CD7和CD95/Fas表达。虽然白细胞介素-6和α干扰素可刺激KMS-12-BM细胞生长，但对KMS-12-PE细胞生长有抑制作用。此外，凋亡抑制因子Bcl-2和Bcl-X(L)在KMS-12-BM细胞中高表达。由于KMS-12-PE比KMS-12-BM早两个月培养，这些差异可能与其来源（胸腔积液和骨髓）或疾病进展阶段有关。然而，这些生物学差异可能有助于阐明骨髓瘤细胞生物学，并改善骨髓瘤患者的治疗。
